{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:36:08Z","timestamp":1785854168206,"version":"3.56.0"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Based on the Adverse Event Reporting System (FAERS) data from the US FDA, this study mined the adverse drug reactions of obeticholic acid (OCA) in the real world and provided reference for clinical safe drug use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse event reports for OCA from the second quarter of 2016 to the third quarter of 2023 were extracted. The analysis for adverse reaction signal detection was conducted using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi\u2010item gamma Poisson shrinker methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 5661 OCA\u2010related adverse event reports were collected, and 105 OCA\u2010related adverse reaction signals were obtained, involving 14 systems, among which 46 new signals were not previously mentioned in the product labeling. Severe adverse event of OCA accounted for a relatively high proportion (1445 cases, 25.53%), among which the number of hospitalization reports was the largest (1042 cases, 18.41%). The top five adverse events were pruritus, fatigue, constipation, elevated blood alkaline phosphatase, and abdominal distention. The top five adverse reaction signals intensity were abnormal blood alkaline phosphatase, abnormal ratio of albumin globulin, spider nevus, combined with abnormal bilirubin, and \u03b3\u2010abnormal glutamyl transferase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Based on the pharmacovigilance study of the FAERS database, it is necessary to strengthen the clinical medication monitoring of OCA, so as to provide reference for effective pharmaceutical monitoring and rational clinical medication.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.70084","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T01:44:38Z","timestamp":1736300678000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Real\u2010World Pharmacovigilance Study of <scp>FDA<\/scp> Adverse Event Reporting System Events for Obeticholic Acid"],"prefix":"10.1002","volume":"34","author":[{"given":"Le","family":"Hai","sequence":"first","affiliation":[{"name":"Hunan Drug Inspection Center  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-0547","authenticated-orcid":false,"given":"Jiaojiao","family":"Wu","sequence":"additional","affiliation":[{"name":"Hunan Institute for Drug Control  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Pan","sequence":"additional","affiliation":[{"name":"Hunan Institute for Drug Control  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Yin","sequence":"additional","affiliation":[{"name":"Hunan Institute for Drug Control  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhishan","family":"Wu","sequence":"additional","affiliation":[{"name":"Hunan Institute for Drug Control  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31607-X"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2018.05.008"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13808-1"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12434"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep25906"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22906"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-014-8456-5"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0616-x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2010.12.006"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509592103"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.212159"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1621\/nrs.08005"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldaa006"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocv153"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862508"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106601"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.716648"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001343"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.013"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31613"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.873404"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)31334-9"},{"issue":"1","key":"e_1_2_9_27_1","first-page":"49","article-title":"Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches","volume":"8","author":"Galoosian A.","year":"2020","journal-title":"Journal of Clinical and Translational Hepatology"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26909"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0350"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.005"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000440829"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64551"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.110.064501"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.01.037"},{"key":"e_1_2_9_35_1","unstructured":"Intercept Pharama \u201cOCALIVA (Obeticholic acid) U. S \u201dhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207999s003lbl.pdf (2023)."},{"issue":"11","key":"e_1_2_9_36_1","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2146\/news180035","article-title":"Summaries of Safety Labeling Changes Approved by FDA\u2010Boxed Warnings Highlights","volume":"75","author":"FDA Current","year":"2018","journal-title":"American Journal of Health\u2010System Pharmacy"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30712-x"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T02:52:40Z","timestamp":1745203960000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/pds.70084"],"URL":"https:\/\/doi.org\/10.1002\/pds.70084","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70084"}}